Influence of the decrease in ciprofloxacin susceptibility and the presence of human serum on the in vitro susceptibility of Streptococcus pneumoniae to five new quinolones

Journal of Antimicrobial Chemotherapy

Volumn 48, Issue 6, 2001, Pages 907-909

  Balcabao, I P ^a   Alou, L ^a   Aguilar, L ^b   Gomez Lus, M L ^a   Gimenez M J ^b   Prieto, J ^a  

^a SCHOOL OF MEDICINE   (Spain)

^b GLAXOSMITHKLINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI INFECTIVE AGENTS, FLUOROQUINOLONE; ANTI INFECTIVE AGENTS, QUINOLONE; CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; PHYSIOLOGY; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS, FLUOROQUINOLONE; ANTI-INFECTIVE AGENTS, QUINOLONE; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; HUMAN; STREPTOCOCCUS PNEUMONIAE; SUPPORT, NON-U.S. GOV'T;

EID: 0035651143     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/48.6.907     Document Type: Article

References (9)

1. Baquero, F., García-Rodríguez, J. A., García de Lomas, J., Aguilar, L. & the Spanish Surveillance Group for Respiratory Pathogens. (1999). Antimicrobial resistance of 1113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996-1997) multicenter surveillance study. Antimicrobial Agents and Chemotherapy 43, 357-9.
2. Garcia-Rey, C., Aguilar, L. & Baquero, F. (2000). Influences of different factors on prevalence of ciprofloxacin resistance in Streptococcus pneumoniae in Spain. Antimicrobial Agents and Chemotherapy 44, 3381-2.
3. Fuentes, F., Giménez, M. J., Marco, F., Alou, L., Aguilar, L. & Prieto, J. (2000). In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin. European Journal of Clinical Microbiology and Infectious Diseases 19, 137-9.
4. Eliopoulos, G. M. (1995). In vitro activity of fluoroquinolones against gram-positive bacteria. Drugs 49, Suppl. 2, 48-57.
5. Woodcock, J. M., Andrews, J. M., Boswell, F. J., Brenwald, N. P. & Wise, R. (1997). In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrobial Agents and Chemotherapy 41, 101-6.
6. National Committee for Clinical Laboratory Standards. (2001). Performance Standards for Antimicrobial Susceptibility Testing - Eleventh Informational Supplement M100-S11. NCCLS, Wayne, PA.
7. Ewing, S., Ruiz, M., Torres, A., Marco, F., Martinez, J. A., Sánchez. M. et al. (1999). Pneumonia acquired in the community through drug-resistant Streptococcuspneumoniae. American Journal of Respiratory and Critical Care Medicine 159, 1835-42.
8. Marchese, A., Debbia, E. A., Pesce, A. & Schito, G. C. (1996). Bactericidal activity, morphological alterations, and synergistic interactions of rufloxacin, a new fluoroquinolone, alone and in combination with its N-desmethylate D derivative (MF 922). Chemotherapy 42, 90-9.
9. Lister, P. D. & Sanders, C. C. (1999). Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 43, 79-86.